UNSPSC 51162330: Atropine/chlorpheniramine/hyoscyamine/phenylephrine/scopolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

UNSPSC 51162330 Atropine/chlorpheniramine/hyoscyamine/phenylephrine/scopolamine is a Commodity code under which state and local governments procure pharmaceutical products, though the recent opportunities show these products as components within broader multi-source generic pharmaceutical and OTC product supply contracts rather than as standalone line items. Issuing bodies include county health departments and state-administered cooperative purchasing alliances; Seminole County, Florida has solicited naloxone and drug deactivation systems for community health initiatives, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, has issued an RFP for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in multiple states including Oregon. The MMCAP procurement represents the larger market signal, establishing contracts for comprehensive pharmaceutical supply through authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with products required to be available by May 15, 2026, and contract terms effective July 1, 2026.

Geographically, recent activity centers on the Upper Midwest and Southeast. The Seminole County, Florida IFB (IFB60459723LAS) released on June 30, 2026 seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. The MMCAP RFP (S1070000015802), posted January 20, 2026 with a proposal deadline of March 26, 2026, explicitly covers Minnesota, Oregon, and other participating jurisdictions through a multi-state cooperative structure. Both opportunities require vendors to submit detailed product information including National Drug Codes, maintain cGMP and Drug Supply Chain Security Act compliance, carry substantial insurance (MMCAP specifies $5 million commercial general liability and $2 million professional liability), and accept administrative fees on contract purchases (MMCAP charges 3 percent with performance penalties ranging from $200 to $1,500 per violation). Neither solicitation identifies explicit set-asides for disadvantaged enterprises.